Brandes Investment Partners LP acquired a new stake in Taro Pharmaceutical Industries Ltd. (NYSE:TARO) during the third quarter, according to its most recent 13F filing with the SEC. The fund acquired 21,836 shares of the company’s stock, valued at approximately $2,460,000. Brandes Investment Partners LP owned 0.05% of Taro Pharmaceutical Industries as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in the stock. Wells Fargo & Company MN increased its position in shares of Taro Pharmaceutical Industries by 11.2% during the second quarter. Wells Fargo & Company MN now owns 1,685 shares of the company’s stock valued at $189,000 after buying an additional 170 shares during the period. Bessemer Group Inc. increased its position in shares of Taro Pharmaceutical Industries by 138.6% during the second quarter. Bessemer Group Inc. now owns 2,083 shares of the company’s stock valued at $234,000 after buying an additional 1,210 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Taro Pharmaceutical Industries during the second quarter valued at about $234,000. Bank of Montreal Can increased its position in shares of Taro Pharmaceutical Industries by 7.5% during the second quarter. Bank of Montreal Can now owns 2,128 shares of the company’s stock valued at $238,000 after buying an additional 149 shares during the period. Finally, Highstreet Asset Management Inc. bought a new stake in shares of Taro Pharmaceutical Industries during the second quarter valued at about $244,000. Institutional investors and hedge funds own 13.30% of the company’s stock.

Shares of Taro Pharmaceutical Industries Ltd. (NYSE TARO) traded up $1.87 on Thursday, hitting $110.18. The stock had a trading volume of 298,000 shares, compared to its average volume of 100,824. Taro Pharmaceutical Industries Ltd. has a 12-month low of $94.00 and a 12-month high of $128.46. The company has a market capitalization of $4,387.96, a PE ratio of 13.34 and a beta of 0.65.

Several equities research analysts have recently weighed in on TARO shares. BidaskClub upgraded Taro Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Thursday, September 28th. TheStreet cut Taro Pharmaceutical Industries from a “b-” rating to a “c+” rating in a research report on Wednesday, August 9th.

COPYRIGHT VIOLATION NOTICE: “Brandes Investment Partners LP Takes $2.46 Million Position in Taro Pharmaceutical Industries Ltd. (TARO)” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/11/30/brandes-investment-partners-lp-takes-2-46-million-position-in-taro-pharmaceutical-industries-ltd-taro.html.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Want to see what other hedge funds are holding TARO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taro Pharmaceutical Industries Ltd. (NYSE:TARO).

Institutional Ownership by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Stock Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.